CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Omnix is developing a new class of antibiotics using bioengineered peptides to combat drug-resistant infections. This innovative approach targets critical pathogens, aiming to demonstrate clinical efficacy and safety, particularly against Acinetobacter baumannii, a high-mortality pathogen. The project seeks to address…
We are in living in times where the efficacy of antibiotics is no longer guaranteed.
Despite the urgent need to mitigate the spread of antimicrobial resistance (AMR), very few antibiotics are being developed. AMR management costs €1.5 B and causes 33,000 deaths each year in the EU.
We at Omnix are determined to change lives and repopulate drug development pipelines by demonstrating clinical efficacy of a novel class of antibiotics.
We have made potent antimicrobial peptides found in nature drugg…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
